...gained rights to Nant-paclitaxel ( Cynviloq ), an injectable nanoparticle formulation of paclitaxel from Samyang Corp. Samyang...
...South Korea Qurient Co. Ltd. (KOSDAQ:115180), Seongnam, South Korea RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md. Samyang Corp....

...cancer. Sorrento has exclusive rights to Cynviloq in North America, the EU and Australia from Samyang Corp....

...rights to the injectable nanoparticle formulation of paclitaxel in Australia, North America and the EU. Samyang...
...provide specific financial details, and Samyang could not be reached (see BioCentury, Feb. 17, 2014). Samyang Corp....

...Inc. (OTCBB:CORX) CX1739 AMPA glutamate receptor (GRIA; GLUR) PAM Phase II Respiratory distress syndrome (RDA) Samyang Corp....

...Australia through its September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:000070). Samyang...

...Cynviloq in the U.S., EU, Mexico, Canada and Australia from Samyang (see BioCentury, Feb. 17). Samyang...
...Genexol-PM. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Abraxane. Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp....

...rights to the injectable nanoparticle formulation of paclitaxel in the U.S. and EU. Last May, Samyang...
...to Sorrento and Igdrasol Inc. and U.S. rights to Igdrasol. Sorrento acquired Igdrasol in September. Samyang...
...breast cancer and non-small cell lung cancer (NSCLC). Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp....

...September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:00070, Seoul, South Korea). Samyang...

...Cynviloq through its September acquisition of Igdrasol Inc. , which has rights from Samyang Corp. (KSE:00070). Samyang...

...acquired exclusive, U.S. rights through the acquisition of Igdrasol Inc. , which received rights from Samyang Corp....